Europe - Frankfurt Stock Exchange - FRA:DMP - DE000A2GS5D8 - Common Stock
The current stock price of DMP.DE is 37.1 EUR. In the past month the price increased by 7.85%. In the past year, price decreased by -1.59%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 10.98 | 202.68B | ||
| SAN.PA | SANOFI | 10.61 | 195.78B | ||
| 1SAN.MI | SANOFI | 10.85 | 200.32B | ||
| MRK.DE | MERCK KGAA | 13.88 | 51.48B | ||
| UCB.BR | UCB SA | 37.09 | 46.31B | ||
| UNC.DE | UCB SA | 36.62 | 45.73B | ||
| BAYN.DE | BAYER AG-REG | 6.74 | 35.37B | ||
| 1BAYN.MI | BAYER AG-REG | 6.78 | 35.56B | ||
| IPN.PA | IPSEN | 11.92 | 10.26B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.51 | 10.10B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 102.28 | 9.47B | ||
| VIRP.PA | VIRBAC SA | 19.55 | 2.84B |
Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The company is headquartered in Gruenwald, Bayern and currently employs 3,551 full-time employees. The company went IPO on 2018-02-09. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
DERMAPHARM HOLDING SE
Lil-Dagover-Ring 7
Gruenwald BAYERN DE
Employees: 3551
Phone: 4989641860
Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The company is headquartered in Gruenwald, Bayern and currently employs 3,551 full-time employees. The company went IPO on 2018-02-09. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
The current stock price of DMP.DE is 37.1 EUR.
DERMAPHARM HOLDING SE (DMP.DE) has a dividend yield of 2.43%. The yearly dividend amount is currently 0.88.
DMP.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for DERMAPHARM HOLDING SE (DMP.DE) is 17.26. This is based on the reported non-GAAP earnings per share of 2.15 and the current share price of 37.1 EUR.
The Revenue of DERMAPHARM HOLDING SE (DMP.DE) is expected to decline by -0.83% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
DERMAPHARM HOLDING SE (DMP.DE) will report earnings on 2026-03-17, after the market close.
ChartMill assigns a technical rating of 8 / 10 to DMP.DE. When comparing the yearly performance of all stocks, DMP.DE turns out to be only a medium performer in the overall market: it outperformed 61.66% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to DMP.DE. DMP.DE has an average financial health and profitability rating.
Over the last trailing twelve months DMP.DE reported a non-GAAP Earnings per Share(EPS) of 2.15. The EPS increased by 28.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10% | ||
| ROA | 5.48% | ||
| ROE | 17.87% | ||
| Debt/Equity | 1.44 |
11 analysts have analysed DMP.DE and the average price target is 42.84 EUR. This implies a price increase of 15.47% is expected in the next year compared to the current price of 37.1.
For the next year, analysts expect an EPS growth of 12.59% and a revenue growth -0.83% for DMP.DE